Legend Biotech’s Post

What are the patient-reported outcomes of liso-cel as a second-line treatment in patients with relapsed/refractory LBCL? Read our summary of the patient-reported outcomes from the phase II PILOT study 👉 https://loom.ly/xuR4x08 #lymsm #lymphoma

Exciting to see the published results of a trial combining our medicines in patients with Richter transformation, an aggressive #lymphoma that may develop in patients with #CLL. Learn more at Nature Medicine here: bit.ly/47rJRsK

Is ibrutinib plus venetoclax a safe and effective treatment for patients with Waldenstrom macroglobulinemia? Check out our visual abstract of a phase II trial here: https://loom.ly/-5o8feo #Waldenstrom #lymsm #lymphoma

Is axicabtagene ciloleucel an effective treatment vs chemoimmunotherapy in older patients and/or patients with a poor ECOG Performance Status with R/R LBCL after ≥2 previous lines of therapy? Find out here: https://loom.ly/G1gEj8s #lymsm #lymphoma #LBCL

Read our latest summary on the 4-year follow-up data from the phase III GLOW trial evaluating ibrutinib + venetoclax in patients with previously untreated CLL here: https://loom.ly/KUJX_kA #lymsm #lymphoma #MedEducation

Underdiagnosis of MASH (Metabolic Dysfunction-Associated Steatohepatitis), coupled with high screen failure in a competitive landscape, continues to slow recruitment of phase II and III trials. By leveraging AI, IQVIA has been able to advance patient identification, while our improved processes for collection and interpretation reduce the risks associated with histological endpoints. Discover how our team of gastroenterology and hepatology clinical development experts are driving innovation in clinical trials. https://bit.ly/4eqv32o #clinicaltrials #MetabolicDysfunctionAssociatedSteatohepatitis #MASH

How does Barrigel impact patient comfort? The Barrigel (NASHA®) rectal spacer remains flexible until it is safely resorbed by the body. The malleable nature of the gel allows the gel to move with the body naturally. There were ZERO reports of patient discomfort in the Barrigel Pivotal Trial. There have been ZERO reports of patient discomfort in the more than 15,000 Barrigel cases to date. #menshealth #Barrigel #PCSM References: 1. Mariados NF, Orio PF, Schiffman Z et al. Hyaluronic acid spacer for hypofractionated prostate radiation therapy: A randomized clinical trial. JAMA Oncol. 2023: e1-e8. 2. Data on file. Palette Life Sciences

Updated efficacy and safety results from cohorts A and B from the CARTITUDE-2 trial were recently presented at #Tandem24. Read our summary of the key results to learn more: https://loom.ly/XyjPzoo #MMsm #MultipleMyeloma #myeloma

According to The Health Management Academy's latest newsletter, service line growth decisions guide investment strategy. “Leaders reported prioritizing cardiovascular, oncology, and neurology service lines. Therefore their investment decisions are tied to innovations supporting these service lines. All of these investments are important as these service lines are seeing patients needing higher acuity care compared to five years ago. To keep cost-per-case under control, many are pursuing innovations focused on earlier detection and preventative care.” What innovations do you want to implement? Let us know in the comments. #defydisease #healthcareinnovation #defydefeatrepeat #AI #cancercare #cancermoonshot

Could cilta-cel be successfully implemented into earlier lines of therapy in #MultipleMyeloma? Read our latest article for a summary of the rationale for incorporating cilta-cel in lines 1–3 and the latest data from CARTITUDE-2 and CARTITUDE-4! 👉 https://loom.ly/6Xo0xac #mmsm #myeloma #CAR-T #RRMM